Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc for GVHD Prophylaxis in Non-Myeloablative Allo-SCT
NCT00948753Phase 2Completed
- Sponsor
- Abramson Cancer Center
- Start
- Jun 2009
- Primary completion
- Apr 2011
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of maraviroc in graft-versus-host disease (GVHD), sponsored by Abramson Cancer Center. Started Jun 2009; status: completed.
02
Drugs
maraviroc
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00948753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00948753.